|Dr. Anat Cohen-Dayag||CEO, Pres & Director||672.39k||N/A||1967|
|Mr. Ari Krashin||Chief Financial & Operating Officer||361.46k||N/A||1973|
|Dr. John J. Hunter Ph.D.||Chief Scientific Officer||496.03k||N/A||1963|
|Mr. Kirk A. Christoffersen||Sr. VP of Corp. & Bus. Devel.||549.34k||N/A||1969|
|Dr. Henry Adewoye M.D.||Chief Medical Officer||564.69k||N/A||N/A|
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.